halometasone and Dermatitis--Atopic

Currently there is no cure for severe atopic dermatitis (AD). Wet-wrap therapy (WWT) has also been used to treat pediatric AD and shown a satisfactory effectiveness, but clinical evidence supporting the use of WWT on severe adult AD is still insufficient.. Twelve patients (eight men and four women) with severe AD (SCORing Atopic Dermatitis [SCORAD] score ≥ 50) treated between January 2015 and September 2017 in our hospital were included. The patients underwent WWT (daily dose: 15 g halometasone cream+100g Vaseline ointment) twice daily for 2 h/session for 7 days. SCORAD, visual analog scale (VAS) for pruritus, investigator's global assessment (IGA), dermatology life quality index (DLQI) scores and serum cortisol levels were determined before and after the WWT.. The patients (mean age: 58.9 ± 18.9 years; range: 27-85 years) had a median disease duration of 27.5 months. After the WWT, the average scores of SCORAD (28.79 ± 5.16 vs. 68.59 ± 8.61, 95%CI: 35.18-44.42), VAS (2.75 ± 0.62 vs. 7.5 ± 1.17, 95%CI: 4.14-5.36), IGA (1.83 ± 0.39 vs. 4.08 ± 0.51, 95%CI: 1.96-2.54), and DQLI score (8.33 ± 1.83 vs. 13.83 ± 2.79, 95%CI: 4.16-6.84) reduced significantly compared with the scores before the WWT (All P < 0.001). However, serum cortisol levels were not affected significantly by the WWT. Four patients complained of tolerable wet dressing-associated discomforts, which was resolved after the wet dressing was removed when the WWT was completed. For the 85-year-old man, serum cortisol levels were lower than the normal value after the WWT (3.67 μg/dL) but restored to the normal levels (13.44 μg/dL) 2 weeks after the WWT was ended. No other adverse events occurred.. WWT can relieve pruritus, reduce skin lesions, and improve quality of life in adult patients with severe AD. Thus, WWT may be effective and safe for severe adult AD. Trial registration No. is ChiCTR1800014909 ( http://www.chictr.org.cn/index.aspx ).

Topics: Adult; Aged; Aged, 80 and over; Bandages; Betamethasone; Dermatitis, Atopic; Dermatologic Agents; Female; Humans; Male; Middle Aged; Petrolatum; Prospective Studies; Pruritus; Quality of Life; Severity of Illness Index

In a double-blind, randomized multicenter study in patients with acute episodes of atopic dermatitis, the efficacy and tolerance of 0.5% halometasone (Sicorten) cream were compared with those of 0.25% prednicarbate cream. A total of 165 patients (88 men, 77 women) were admitted to the study. The halometasone group contained 9% more cases with severe disease than did the prednicarbate group. Two daily nonocclusive applications were permitted, and treatment lasted 14 days. No difference in the onset of the effect was observed between the two groups. With respect to clinical efficacy, higher healing rates were found in the halometasone group: 50.6% versus 34.5% in the patients as a whole, and 39.5% vs. 16.2% in the subgroup of clinically severe cases. Applying stratification, a statistical difference was found in the clinically severe cases. Both creams were well tolerated; undesired side effects were observed neither with halometasone cream nor with prednicarbate cream. Cosmetic acceptance was assessed as very good by 50.6% of patients treated with halometasone cream, and 46.0% of patients treated with prednicarbate cream. Summarizing, it may be noted that halometasone cream is more effective than prednicarbate cream, and is equally well tolerated.

Topics: Acute Disease; Administration, Topical; Adolescent; Adult; Anti-Inflammatory Agents; Betamethasone; Child; Child, Preschool; Dermatitis, Atopic; Double-Blind Method; Female; Humans; Infant; Male; Middle Aged; Ointments; Prednisolone

In an open non-comparative trial 247 eczema patients were treated with Sicorten topicals. Sicorten cream yielded good to very good results in 90%, 97% and 100% of the patients suffering from atopic dermatitis, contact dermatitis and seborrhoeic dermatitis, respectively, while Sicorten ointment produced similar results in 97% and 100% of the patients with chronic atopic dermatitis and chronic contact dermatitis, respectively. In a double-blind trial involving 108 patients suffering from atopic, seborrhoeic or contact dermatitis, the therapeutic effect of Sicorten and Betnelan creams and ointments was not significantly different.

Topics: Administration, Topical; Adult; Betamethasone; Betamethasone Valerate; Child; Clinical Trials as Topic; Dermatitis, Atopic; Dermatitis, Contact; Dermatitis, Seborrheic; Double-Blind Method; Humans; Ointments

C 48.401-Ba cream, containing 0.05% halomethasone was compared in a double-blind between-patients trial with a cream containing 0.1% betamethasone valerate in forty-eight patients suffering from atopic dermatitis and in thirty-nine patients suffering from seborrhoeic dermatitis. A similar comparison was made with ointments containing the same concentration of active ingredient in forty-six patients suffering from atopic dermatitis. Both ointments were also compared in a within-patient double-blind trial in thirty patients suffering from psoriasis. The analysis of the results showed that for the treatment of the above-mentioned dermatoses, both drugs, the cream as well as the ointment, are equally effective and well tolerated.

Topics: Administration, Topical; Anti-Inflammatory Agents; Betamethasone; Betamethasone Valerate; Clinical Trials as Topic; Dermatitis, Atopic; Dermatitis, Seborrheic; Double-Blind Method; Humans; Psoriasis